Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus

U

University Hospital, Gentofte, Copenhagen

Status

Completed

Conditions

Glucagon-like Peptide-1
Blod Pressure
Blood Flow
Human Physiology
Type 2 Diabetes

Treatments

Other: human glucagon-like peptide 1 (7-36)amide
Other: human glucagon-like peptide 1 (9-36)amide

Study type

Interventional

Funder types

Other

Identifiers

NCT01689051
1-Sivertsen

Details and patient eligibility

About

Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected. This increases the number of patients with heart disease, and since the vast majority with diabetes die from heart disease, it is extremely important to investigate how these diseases can be prevented and treated. Studies in animals have shown that intestinal hormone glucagon-like peptide-1 (GLP-1) can expand blood vessels, thus lowering blood pressure, but it is not known whether the effects is found in humans, which we will investigate. Studies have also shown that GLP-1 lowers blood sugar, but it is unclear whether this is solely due to increased insulin production, weight loss associated with GLP-1 intake or GLP-1 has an effect on the muscles which increases the uptake of sugar. We investigate whether GLP-1 enhances the absorption of sugar in the leg. The investigators also examines whether these effects are greater in people with diabetes then in healthy.

Enrollment

20 patients

Sex

Male

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Written informed consent
  • T2DM according to WHO's criteria (only T2DM subjects)

Exclusion criteria

  • Anemia
  • T1DM
  • Severe liver or renal disease
  • Severe heart disease
  • Atrial fibrillation

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

20 participants in 2 patient groups

Healthy subjects
Active Comparator group
Treatment:
Other: human glucagon-like peptide 1 (9-36)amide
Other: human glucagon-like peptide 1 (7-36)amide
Patients with type 2 diabetes
Active Comparator group
Treatment:
Other: human glucagon-like peptide 1 (9-36)amide
Other: human glucagon-like peptide 1 (7-36)amide

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems